{"disease":{"id":"endometrial-undifferentiated-carcinoma","name":"endometrial undifferentiated carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03914612","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":813,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02065687","title":"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":469,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":true},{"nct_id":"NCT05256225","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03660826","title":"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":288,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00492778","title":"Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":165,"lead_sponsor_name":"GOG Foundation","has_results":true},{"nct_id":"NCT05112601","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04092270","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00888173","title":"Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":true},{"nct_id":"NCT02020707","title":"Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03241745","title":"A Study of Nivolumab in Selected Uterine Cancer Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT03120624","title":"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT00575952","title":"Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT01935973","title":"Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01440998","title":"Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04719273","title":"Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT02728258","title":"Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"NRG Oncology","has_results":true},{"nct_id":"NCT05390021","title":"PET/MRI in Endometrial Cancer","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}